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Abstract
Every year 170,000 patients are diagnosed with brain metastases (BMs) in the United States. Traditionally, adjuvant
whole brain radiotherapy (AWBRT) has been offered following local therapy with neurosurgery (NSx) and/or
stereotactic radiosurgery (SRS) to BMs. The aim is to increase intracranial control, thereby decreasing symptoms from
intracranial progression and a neurological death. There is a rapidly evolving change in the radiation treatment of BMs
happening around the world. AWBRT is now being passed over in favour of repeat scanning at regular intervals and
more local therapies as more BMs appear radiologically, BMs that may never become symptomatic. This change has
happened after the American Society for Radiation Oncology (ASTRO) in Item 5 of its “Choosing Wisely 2014” list
recommended: “Don't routinely add adjuvant whole brain radiation therapy to SRS for limited brain metastases”.
The guidelines are supposed to be based on the highest evidence to hand at the time. This article debates that the
randomised controlled trials (RCTs) published prior to this recommendation consistently showed AWBRT significantly
increases intracranial control, and avoids a neurological death, what it is meant to do. It also points out that, despite
the enormity of the problem, only 774 patients in total had been randomised over more than three decades.
These trials were heterogeneous in many respects. This data can, at best, be regarded as preliminary. In particular,
there are no single histology AWBRT trials yet completed. A phase two trial investigating hippocampal avoiding AWBRT
(HAWBRT) showed significantly less NCF decline compared to historical controls. We now need more randomised data
to confirm the benefit of adjuvant HAWBRT. However, the ASTRO Guideline has particularly impacted accrual to trials
investigating this, especially the international ANZMTG 01.07 WBRTMel trial. This is an RCT investigating AWBRT
following local treatment in patients with one to three BMs from melanoma. WBRTMel has accrued 196 of a required
220 to date but accrual has slowed. HAWBRT may now never be tested in a randomised setting. Encouraging more
data in AWBRT is the wiser choice.
Background
Brain metastases (BMs) are a significant problem, every
year 170,000 patients are diagnosed BMs with in the
United States [1]. Traditionally, for oligo metastatic
disease (1–4 BMs), adjuvant whole brain radiotherapy
(AWBRT) has been offered following local therapy to
BMs, which include neurosurgery (NSx) and/or ste-
reotactic radiosurgery (SRS). The aim of the AWBRT is to
increase intracranial control, thereby preventing or delaying
symptoms from intracranial progression and a neurological
death, perhaps even extending survival.
There is a rapidly evolving change in the radiation treat-
ment of BMs happening around the world. AWBRT is now
being passed over in favour of repeat scanning at regular
intervals and more local therapies as more BMs appear
radiologically, BMs that may never become symptomatic.
This change may not be in the best interests of
patients, nor of health systems. Patients later in their
cancer journey may not be able to access repeat scan-
ning, meaning that some may suffer from intracranial
progression and die a neurological death anyway. There
may be over treatment with more expensive rescanning
and more local therapies like SRS of lesions that were
never going to be a problem. All of this is not great palli-
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This change has happened after the American Society
for Radiation Oncology (ASTRO) in Item 5 of its “Choos-
ing Wisely 2014” list recommended: “Don’t routinely add
adjuvant whole brain radiation therapy to SRS for limited
brain metastases” [2]. On what basis has this recommen-
dation been made? Is it a truly wise statement?
Discussion
The randomised controlled trials (RCT) investigating
AWBRT published prior to this recommendation are
few (Table 1). In these trials, AWBRT has consistently
resulted in what it is meant to do. AWBRT significantly
increases intracranial control, and avoids a neurological
death. There are negative points about these trials. Des-
pite the enormity of the problem, only 774 patients in
total have been randomised over more than three
decades. The numbers in each trial are small. Two of the
five trials, Chang et al. and Roos et al. did not complete
accrual, meaning that they are, at best, hypothesis gener-
ating. Within each accrual has been slow, often taking
over a decade for a reasonably sized trial. The trials are
heterogeneous in many respects. The trials included
BMs of all histologies of solid malignancies. Most partic-
ipants had either lung or breast cancer. Patients with
lung or breast cancer can have life style characteristics
(eg. smoking) and multiple previous systemic chemo-
therapies that can impact secondary endpoints such as
quality of life (QoL) and neurocognitive function (NCF)
[3]. The trials differed in the number of BMs allowed,
radiotherapy total dose, and dose per fraction, these
factors also being important for secondary endpoints.
The recent abstract of the Alliance trial presented by
Brown at American Society of Clinical Oncology
(ASCO) 2015 is a welcome addition to the field. This
trial also took over a decade to accrue and comprised
BMs of all histologies. The peer – reviewed publication
is awaited [4].
These trials are the only published randomised data on
AWBRT that exists. In these trials, AWBRT delivered what
it was meant to. This data in total can, at best, be regarded
as preliminary. In particular, there are no single histology
AWBRT trials yet completed. However, the ASTRO rec-
ommendation is opposed to the conclusions of this data.
On what data then is the ASTRO recommendation
based? Some SRS enthusiasts have produced a meta-
analysis [5, 6], based on the above trials, of 364 selected
patients treated with SRS. They conclude that AWBRT
should be discouraged as it does not increase overall
survival (OS). The findings of the study actually make
AWBRT look good. These are tabulated in Table 2 from
the figures given in the article. The addition of AWBRT
was associated with less local and distant failure, less
requirement for local and distant salvage, and less
neurological death even in this selected cohort. The
addition of AWBRT was also associated with an increase
in time to local failure (median from 6.6 to 7.4 months,





















96/8 All 60 % lung 50.4/28 Single 11 Yes Yes No
Aoyama 2007
[11, 12] Complete
132/4 All 65 % lung 30/12 1–4 8 Yes No difference No
Chang 2009
[14] Incomplete
58/6 All 55 % lung 30/10 1–3 9.2 Yes No difference Yes
Roos 2011
[22] Incomplete
19/3 All 30/10 Single NA NA NA No
Kocher 2011
[23] Complete
359/12 All 50 % lung 30/10 1–3 10.9 Yes Yes No








Impact of addition of
AWBRT on parameter
Failure at Local site (as % of totals) 72 (20 %) 51 (27 %) 21 (12 %) Decreases
Salvage at Local site (as % of fails) 45 (63 %) 37 (73 %) 8 (38 %) Decreases
Failure of Distant brain(as % of totals) 156 (43 %) 98 (53 %) 58 (34 %) Decreases
Salvage of Distant brain (as % of fails) 100 (64 %) 72 (73 %) 28 (48 %) Decreases
Neurologic deaths (as % of totals) 99 (27 %) 55 (30 %) 44 (25 %) Decreases
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mean from 11 to 13 months) and time to distant failure
(median from 4.7 to 6.5 months and the mean from 9.6
to 12 months). This meta-analysis has already been
criticised [7] in the cancer literature. Additional statis-
tical criticisms include that in the article there are no
measures of inter-trial consistency reported, as recom-
mended by meta-analysis guidelines [8, 9]. These reports
are important as inconsistency of trial homogeneity in a
meta-analysis reduces the significance of the findings
[10]. The authors also miss the point. AWBRT is essen-
tially a palliative treatment and is primarily about symp-
tom control rather than increasing survival.
An interesting twist is the recent publication by Aoyama
et al. [11, 12] of a subgroup re-analysis of 88 patients with
non–small cell lung cancer (NSCLC) in the same 2007
Aoyama trial as used in the meta-analysis. Using the
disease-specific Graded Prognostic Assessment (ds-GPA),
a prognostic stratification tool, the median overall survival
time of the favourable group (ds-GPA of 2.5 to 4; 47 pa-
tients) was 16.7 versus 10.6 months in the unfavorable
group (ds-GPA of 0.5 to 2; 41 patients) [13]. There was a
survival advantage in the AWBRT arm over SRS alone
(p = 0.03) for the favourable group. A similar survival
improvement was not observed in the unfavourable
group. One possible explanation could be that for
patients with a high ds-GPA category, improved brain
control allows them to have more systemic therapy
and therefore a survival advantage. This sub-study is
hypothesis generating, but does confirm the need to
consider the histology of the primary cancer and
other patient data such as performance status. It also
exposes the selection bias and the impact of small
numbers in the meta-analysis.
The incompletely accrued Chang trial also showed that
AWBRT may be associated with NCF problems in longer
term survivors [14]. To address this problem, Gondi et al.
have published a phase two trial investigating hippocam-
pal avoiding AWBRT (HAWBRT) [15]. This study showed
significantly less NCF decline compared to historical
controls. We now need more randomised data to confirm
the benefit of adjuvant HAWBRT in intracranial control
and NCF preservation.
SRS is also not completely benign. As these patients
are living longer, the risk of SRS complications, such as
radionecrosis (RN), increases. There may also be a dele-
terious interaction between SRS and new therapies that
may be greater than the interaction with AWBRT alone
[16]. Upfront SRS may also risk disappearing in the era
of better systemic therapies. A recent trial randomised
105 NSCLC good performance patients with 1–4 BMs,
most of them solitary, to either SRS or observation prior
to systemic chemotherapy [17]. The median OS time of
the whole cohort was 15 months and there was no
significant difference between the groups in terms of
time to symptomatic progression of BMs, overall central
nervous system (CNS) disease progression, or median
OS. SRS also did not lead to increased overall survival in
this RCT. Should SRS also be dispensed with? Further
studies are needed.
The currently accruing international ANZMTG 01.07
WBRTMel trial is investigating AWBRT following local
treatment in patients with one to three BMs from mel-
anoma [18]. The ANZMTG 01.07 protocol was first ap-
proved by the Cancer Institute NSW Lead Ethics
Committee on 20 December 2007 (reference: 2007C/11/
032). It is the world’s first single histology AWBRT trial.
This trial has all the appropriate NCF measurements
and allows HAWBRT. It has accrued 179 of a required
200 to date. Interim analysis has shown the collected
data is of high quality [19]. However, trial accrual is
decreasing as investigators are not offering the trial
because of the ASTRO recommendation. The ASTRO
recommendation is stopping much needed data about
AWBRT being collected. HAWBRT may never be tested
in a randomised setting. ASTRO needs to retract its
recommendation.
Conclusion
BMs are a significant problem. AWBRT is an effective pal-
liative treatment that is based on RCT evidence. Withhold-
ing AWBRT leads to a definitive increase in intracranial
relapse, not all relapse can be salvaged by Sx or SRS, leads
to an Increased cost of observation and managing relapse.
It may stop a reduction in neurocognitive decline but the
data is weak, and the impact on overall survival is still to
be defined. More RCT are needed to improve on AWBRT
especially in single histology trials and trials that test
HAWBRT. HAWBRT may improve the toxicity profile, es-
pecially NCF and needs an RCT to show this.
ASTRO has recently recommended don’t routinely
add WBRT to SRS for limited brain metastases as ran-
domized studies have demonstrated no overall survival
benefit from the addition of AWBRT to SRS. However,
these trials show AWBRT is effective in what it was
meant to do and were never powered for OS. Another
reason was that the addition of AWBRT to SRS is asso-
ciated with diminished cognitive function and worse
patient-reported fatigue and quality of life, but at the
time this was based on an incomplete trial and data sets.
A further reason was that careful surveillance and the
judicious use of salvage therapy at the time of brain
relapse allows appropriate patients to enjoy the highest
QoL without a detriment in overall survival but there
was no high level of evidence for this. This recommen-
dation is not based on the existing randomised evidence,
in fact, the randomised evidence supports the use of
AWBRT in oligo metastatic disease. The ASTRO recom-
mendation is impacting accrual to the world’s first single
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histology trial. AWBRT is being phased out just when
radiation oncologists had produced a better radiotherapy
technique, HAWBRT, to answer some of these criticisms.
ASTRO should consider retracting its recommendation.
Encouraging more data in AWBRT is the wiser choice.
The real question to ask is: why are RCT in AWBRT so
hard to accrue to when the problem is so common? Studies
of poor trial accrual mention many possible factors, but it
may be a lack of physician equipoise. This has been found
in other cancer types [20]. Lack of equipoise can be driven
by many factors, including firmly held views despite little
data, fear of losing revenue, and over reliance on phase one
and phase two and retrospective data. May the quest for
higher level evidence re - invigorate trials in AWBRT.
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